Genetic mutations that cause Friedreich’s ataxia (FA) arise from a previously unrecognized category of FXN gene variants called a…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Two microRNAs (miRNAs) — molecules that help regulate gene activity — may serve as biomarkers of cardiomyopathy in people with…
Biogen’s Skyclarys (omaveloxolone) is one step closer to being covered by Quebec public healthcare systems for people with…
Brain scans of people with Friedreich’s ataxia (FA) revealed reduced communication between the frontal cortex and the cerebellum, two-interconnected…
Scientists have created and validated stem cell lines derived from an adult with Friedreich’s ataxia (FA) carrying an ultra-rare…
In adults with Friedreich’s ataxia (FA), a brain communication pathway connecting the cerebellum to the motor cortex, which…
Skyclarys (omaveloxolone) improved key measures of function and cellular health in nerve cells from the dorsal root ganglia, clusters…
Researchers have developed a new type of gene therapy that, according to the findings of a new study in animal…
Sensors worn while walking at a natural pace can accurately distinguish people with Friedreich’s ataxia (FA) from those without…
MRI scans analyzed with artificial intelligence (AI) to measure the size of the dentate nucleus — a deep brain region…